You can also search for this author in 2016 Feb 28;157(9):336-41. doi: 10.1556/650.2016.30323.Curr Opin Hematol. 2006 Mar;13(2):93-8. doi: 10.1097/01.moh.0000208470.86732.b4.Cozzani E, Iurlo A, Merlo G, Cattaneo D, Burlando M, Pierri I, Gugliotta L, Parodi A.Clin Lymphoma Myeloma Leuk. J Clin Oncol 1990; 8: 556–62.Barbui T, Barosi G, Grossi A, et al.
Haematologica. N Engl J Med 2005; 352: 1779–90.Campbell P, Scott LM, Buck G, et al. Concise summaries and expert physician commentary that busy clinicians need to enhance patient care.The most effective and engaging way for clinicians to learn, improve their practice, and prepare for board exams.NEW! The treated patients were seen every two weeks until the platelet count was below 600,000 per cubic millimeter, and at least every two months thereafter. Acta Haematol 1987; 78: 41–4.Murphy S, Peterson P, Hand H, Laszlo J.
Essential thrombocythemia belongs to a group of diseases called myeloproliferative neoplasms, which cause the bone marrow to make too many platelets, white blood cells and/or red blood cells.In essential thrombocythemia, the body produces too many platelets. The V617FJak2 mutation and the myeloproliferative disorders. Free PMC article Tick marks indicate surviving patients who were continuously free of thrombosis.Sixteen patients (14 percent) had thrombotic complications (Ten of 16 patients with thrombosis (62.5 percent) — 2 in the hydroxyurea group and 8 in the control group — had been taking aspirin (n = 6) or ticlopidine (n = 4) before thrombosis occurred, as compared with 69 of 98 asymptomatic patients (70 percent). Topics: myeloproliferative disease, thrombocythemia, hemorrhagic, polycythemia vera, myelofibrosis, idiopathic, chronic, mutation, phenotype. Essential thrombocythemia is one of the myeloproliferative neoplasms with a plethora of thrombohemorrhagic complications.Hydroxyurea has been proven to be an effective treatment for this condition. This site needs JavaScript to work properly. The two groups were matched for age, sex, and platelet count at randomization. By contrast, there were 14 vascular occlusive events in the 58 untreated controls.
Awareness of this important treatment complication is important to avoid the pitfall of futile invasive interventions. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and Jak2 mutation status.
In sickle-cell disease it increases fetal hemoglobin and decreases the number of attacks. The median age at diagnosis is 65 to 70 years, but the disease may occur at any age. Zalcberg IR, Ayres-Silva J, de Azevedo AM, Solza C, Daumas A, Bonamino M. Zalcberg IR, et al. Subscription will auto renew annually.Over 10 million scientific documents at your fingertips You can also search for this author in We assessed whether maintaining the platelet count below 600,000 per cubic millimeter with hydroxyurea reduces the incidence of thrombosis in patients with essential thrombocythemia and a high risk of thrombosis.A total of 114 patients with essential thrombocythemia (77 women and 37 men; median age, 68 years; range, 40 to 85) and a median platelet count of 788,000 per cubic millimeter (range, 533,000 to 1,240,000 per cubic millimeter) were randomly assigned to receive hydroxyurea (56 patients) or no myelosuppressive therapy (58 patients).